Pretransplant soluble CD30 serum concentration does not affect kidney graft outcomes 3 years after transplantation

Transplantation Proceedings

Volumn 42, Issue 10, 2010, Pages 4043-4046

  Kovac J ^a   Arnol, M ^b   Vidan Jeras, B ^b   Bren, A F ^a   Kandus, A ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD30 ANTIGEN; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; ADULT; CADAVER KIDNEY; COHORT ANALYSIS; CONFERENCE PAPER; CONTINUOUS INFUSION; DELAYED GRAFT FUNCTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSPLANTATION TOLERANCE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; COHORT STUDIES; CYCLOSPORINE; FEMALE; FLOW CYTOMETRY; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 78650477620     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.09.050     Document Type: Conference Paper

References (23)

1. O. Josimovic-Alasevic, H. Durkop, and R. Schwarting Ki-1 (CD30) antigen is released by Ki-1 positive tumor-cells in vitro and in vivo I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme- linked immunosorbent assay Eur J Immunol 19 1989 157
2. G. Del Prete, M. De Carli, and M.M. D'Elios CD30-mediated signaling promotes the development of human T helper type 2-like T cells J Exp Med 182 1995 1655
3. G. Del Prete, M. De Carli, and F. Almerigogna Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines FASEB J 9 1995 81
4. S. Romagnani, P. Parronchi, and M.M. D'Elios An update on human Th1 and Th2 cells Int Arch Allergy Immunol 113 1997 153
5. S. Pelzl, G. Opelz, and M. Wieser Soluble CD30 as a predictor of kidney graft outcome Transplantation 73 2002 3
6. C. Ssal, S. Pelzl, and B. Dohler Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30 J Am Soc Nephrol 13 2002 1650
7. C. Ssal, S. Pelzl, and G. Opelz Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30 Transplantation 76 2003 1231
8. C. Ssal, S. Pelzl, and T. Simon Advances in pre- and posttransplant immunologic testing in kidney transplantation Transplant Proc 36 2004 29
9. P. Cinti, R. Pretagostini, and A. Arpino Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations Transplantation 79 2005 599
10. R. Ravindra, J. Naina, and V. Mira High pre-transplant soluble CD30 levels are predictive of the grade of rejection Am J Transplant 5 2005 1922
11. M.S. Kim, H.J. Kim, and S.I. Kim Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation Transplantation 82 2006 1602
12. S. Vaidya, D. Parlow, and T. Barnes Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies Transplantation 82 2006 1606
13. S. Sengul, K. Keven, and U. Gormez Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble cd30 levels in kidney transplantation Transplantation 81 2006 1216
14. A. Kandus, K. Grego, and M. Arnol Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience Transplant Proc 38 2006 2853
15. A. Kandus, K. Grego, and A.F. Bren Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients Ther Apher Dial 9 2005 262
16. U. Pge, T. Gerhardt, and H. Palmedo MDRD equations for estimation of GFR in renal transplant patients Am J Transplant 5 2005 1306
17. E.D. Poggio, X. Wang, and D.M. Weinstein Assessing glomerular filtration rate by estimation equations in kidney transplant recipients Am J Transplant 6 2006 100
18. P.I. Terasaki, and J. McCleland Microdroplet assay of human serum cytotoxins Nature 204 1964 998
19. B.L. Kasiske, M.A. Vazquez, and W.E. Harmon Recommendations for the outpatient surveillance of renal transplant recipients J Am Soc Nephrol 11 suppl 15 2000 S1
20. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Kidney Disease Outcome Quality Initiative Am J Kidney Dis 39 2 suppl 1 2002 S1
21. F.M. Heinemann, V. Rebmann, and O. Witzke Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation Transplantation 83 2007 706
22. K.L. Womer, J.P. Vella, and M.H. Sayegh Chronic allograft dysfunction: mechanisms and new approaches to therapy Semin Nephrol 20 2000 126
23. A.O. Ojo, R.A. Wolfe, and P.J. Held Delayed graft function: risk factors and implications for renal allograft survival Transplantation 63 1997 968